Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

ATR anticorps (C-Term)

KO Validated ATR Reactivité: Humain WB, IP, ICC, IHC (p), IF Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7467983
  • Antigène Voir toutes ATR Anticorps
    ATR (Ataxia Telangiectasia and Rad3 Related (ATR))
    Épitope
    • 2
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reactivité
    • 7
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 5
    • 2
    Lapin
    Clonalité
    • 5
    • 2
    Polyclonal
    Conjugué
    • 7
    Cet anticorp ATR est non-conjugé
    Application
    • 6
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)
     Réactivité croisée
    Humain, Souris
    Purification
    Purified by antigen-affinity chromatography.
    Classe de qualité
    KO Validated
    Immunogène
    Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human ATR. The exact sequence is proprietary.
    Isotype
    IgG
    Top Product
    Discover our top product ATR Anticorps primaire
  • Indications d'application
    WB: 1:500-1:3000. ICC/IF: 1:100-1:5000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.
    Commentaires

    Positive Control: 293T , A431 , HeLa , HepG2 , Raji nuclear extract Validation: Comparison, KO/KD, Orthogonal

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    1XPBS pH 7, 1 % BSA, 20 % Glycerol, 0.025 % ProClin 300
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
  • Antigène
    ATR (Ataxia Telangiectasia and Rad3 Related (ATR))
    Autre désignation
    ATR serine/threonine kinase (ATR Produits)
    Synonymes
    anticorps ATR, anticorps si:dkey-231j24.1, anticorps FCTCS, anticorps FRP1, anticorps MEC1, anticorps SCKL, anticorps SCKL1, anticorps XATR, anticorps frp1, anticorps mec1, anticorps sckl, anticorps sckl1, anticorps ARABIDOPSIS THALIANA ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED, anticorps ATATR, anticorps ATRAD3, anticorps Ataxia telangiectasia-mutated and RAD3-related, anticorps MHK7.5, anticorps MHK7_5, anticorps ataxia telangiectasia and Rad3 related, anticorps ATR serine/threonine kinase, anticorps ATR serine/threonine kinase L homeolog, anticorps Ataxia telangiectasia-mutated and RAD3-like protein, anticorps Atr, anticorps ATR, anticorps atr, anticorps atr.L
    Sujet

    Synonyms: ATR serine/threonine kinase , FCTCS , FRP1 , MEC1 , SCKL , SCKL1

    Background: The protein encoded by this gene belongs the PI3/PI4-kinase family, and is most closely related to ATM, a protein kinase encoded by the gene mutated in ataxia telangiectasia. This protein and ATM share similarity with Schizosaccharomyces pombe rad3, a cell cycle checkpoint gene required for cell cycle arrest and DNA damage repair in response to DNA damage. This kinase has been shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1. Mutations of this gene are associated with Seckel syndrome. An alternatively spliced transcript variant of this gene has been reported, however, its full length nature is not known. Transcript variants utilizing alternative polyA sites exist. [provided by RefSeq]

    Poids moléculaire
    301 kDa
    ID gène
    545
    UniProt
    Q13535
    Pathways
    Signalisation p53, Apoptose, Réparation de l'ADN, Positive Regulation of Response to DNA Damage Stimulus
Vous êtes ici: